期刊
BRITISH JOURNAL OF PHARMACOLOGY
卷 165, 期 4, 页码 820-828出版社
WILEY-BLACKWELL
DOI: 10.1111/j.1476-5381.2011.01614.x
关键词
IBD; Crohn's disease; ulcerative colitis; anti-TNF; anti-IL-12; anti-IL-6R; cytokines
资金
- 'Fondazione Umberto Di Mario' (Rome, Italy)
- Giuliani Spa (Milan, Italy)
Gut inflammation occurring in patients with inflammatory bowel diseases (IBD) is associated with an excessive immune response that is directed against constituents of the normal bacterial flora and results in the production of large amounts of inflammatory cytokines. Anti-cytokine compounds, such as the neutralizing TNF antibodies, have been employed with clinical success in patients with IBD. However, nearly half of IBD patients are refractory to such treatments, response can wane with time, and anti-TNF treatment can associate with severe side effects and/or development/exacerbation of extra-intestinal immune-mediated pathologies. These observations, and the demonstration that, in IBD, the pathological process is also characterized by defects in the production and/or activity of counter-regulatory cytokines, have boosted further studies aimed at delineating novel strategies to combat the IBD-associated tissue-damaging immune response.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据